share_log

Recursion Pharmaceuticals | DEFA14A: Others

Recursion Pharmaceuticals | DEFA14A: Others

Recursion Pharmaceuticals | DEFA14A:其他
美股sec公告 ·  04/23 17:21
Moomoo AI 已提取核心信息
Recursion Pharmaceuticals, Inc., a company listed in the United States, has filed definitive additional materials with the Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicates that the materials are intended for further communication with the company's shareholders in relation to the proxy statement. The company has confirmed that no filing fee is required for this submission. The exact nature of the additional materials was not specified in the announcement.
Recursion Pharmaceuticals, Inc., a company listed in the United States, has filed definitive additional materials with the Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicates that the materials are intended for further communication with the company's shareholders in relation to the proxy statement. The company has confirmed that no filing fee is required for this submission. The exact nature of the additional materials was not specified in the announcement.
在美国上市的公司Recursion Pharmaceuticals, Inc. 已向美国证券交易委员会(SEC)提交了明确的补充材料,作为其委托书的一部分。根据1934年《证券交易法》第14(a)条,该文件表明,这些材料旨在与公司股东就委托书进行进一步沟通。该公司已确认本次提交不需要任何申请费。公告中没有具体说明额外材料的确切性质。
在美国上市的公司Recursion Pharmaceuticals, Inc. 已向美国证券交易委员会(SEC)提交了明确的补充材料,作为其委托书的一部分。根据1934年《证券交易法》第14(a)条,该文件表明,这些材料旨在与公司股东就委托书进行进一步沟通。该公司已确认本次提交不需要任何申请费。公告中没有具体说明额外材料的确切性质。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息